Skip to main content
SpringerLink
Log in

Post-marketing Surveillance (PMS)

  • Chapter
The Detection of New Adverse Drug Reactions

  • 18 Accesses

Abstract

Since the thalidomide disaster the momentum of post-marketing surveillance has increased in an exponential way and in recent years there have been many symposia and books devoted to the subject. This chapter hopes to outline the problems involved and give reference to the most important sources of information.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Deitch, R. Adverse reactions to drugs. Lancet, 1980, May 17, 1095

    Google Scholar 

  2. Harrow, D.W.G., Griffiths, K. and Shanks, R.G. Debendox and congenital malformations in Northern Ireland. Br. Med. J., 1980, 281, 1274–1381

    Google Scholar 

  3. Anon. Pertussis vaccine. Br. Med. J., 1981, 282, 1563

    Google Scholar 

  4. Anon. Crying wolf on drug safety. Br. Med. J., 1982, 284, 219

    Google Scholar 

  5. Anon. Hunting rare adverse drug reactions. Br. Med. J., 1981, 282, 342–343

    Google Scholar 

  6. Martys, C.R. Adverse reactions to drugs in general practice. Br. Med. J., 1979, 2, 1194–1197

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Gifford, L.M., Aeugle, M.E., Myerson, R.N. and Tannenbaum, P.J. Cimetidine postmarket outpatient surveillance program. J.A.M.A., 1980, 243(15), 1532

    Article  PubMed  CAS  Google Scholar 

  8. Rawlins, M.D. and Dollery, C.T. Postmarketing surveillance of adverse reactions to new medicines. Medico-pharmaceutical Forum Publication No. 7, 1977, 40

    Google Scholar 

  9. Boman, G. The nordic countries. In Monitoring for Drug Safety (ed. W.H.W. Inman), MTP, 1980

    Google Scholar 

  10. Liljestrand. In Drug Induced Sufferings: Medical, Pharmaceutical and Legal Aspects (ed. T. Soda), Excerpta Medica, Amsterdam, 1980, p. 234

    Google Scholar 

  11. Inman, W.H.W. and Mustrin, W.W. Jaundice after repeated exposure to halothane: an analysis of reports to the Committee on Safety of Medicines. Br. Med. J., 1974, 1(5)

    Google Scholar 

  12. Griffin, J.P. Postmarketing surveillance of licensed medicinal and other products. Health Trends, 1981, 13, 87

    Google Scholar 

  13. Inman, W.H.W. and Vessey, M.P. Investigation of deaths from pulmonary, coronary and cerebral thrombosis and embolism in women of childbearing age. Br. Med. J., 1968, 2, 193–199

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Inman, W.H.W., Vessey, M.P. Westerholm, B. and Engelind, A. Thromboembolic disease and the steroidal content of oral contraceptives. Br. Med. J., 1970, 2, 203

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Cahal, D.A. Adverse reactions to nalidixic acid. Lancet, 1965, i, 441

    Article  Google Scholar 

  16. Wade. G.L. In Adverse Drug Reactions (ed. D.J. Richards and R.K. Rondel), Churchill Livingstone, Edinburgh, 1972, p. 52

    Google Scholar 

  17. Anon. How the yellow card system might be improved. Pharm. J., 1983, 231, 6 Aug, 160

    Google Scholar 

  18. Inman, W.H.W. and Rawson, N.S.B., Erythromycin estolate and jaundice, Br. Med. J., 1983, 286, 1954–1955

    Article  CAS  Google Scholar 

  19. Venning, G.R., Identification of adverse reactions to new drugs: 1. What have been the important adverse reactions since thalidomide? Br. Med. J., 1983, 286, 199–202

    Article  CAS  Google Scholar 

  20. Venning, G.R. Identification of adverse reactions to new drugs: 2. How were 18 important adverse reactions discovered and with what delays? Br. Med. J., 1983, 286, 289–292, 365–368

    Article  CAS  Google Scholar 

  21. Venning, G.R., Identification of adverse reactions to new drugs: 3. Alerting processes and early warning systems. Br. Med. J., 1983, 286, 458–460

    Article  CAS  Google Scholar 

  22. Venning, G.R. Identification of adverse reactions to new drugs: 4. Verification of suspected adverse reactions. Br. Med. J., 1983, 286, 544–547

    Article  CAS  Google Scholar 

  23. Lasagna, L. Techniques for ADR reporting. In Detection and Prevention of Adverse Drug Reaction (ed. H. Boström and N. Ljungstedt), Almqvist and Wiksell, Stockholm

    Google Scholar 

  24. Venning, G.R., Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. Br. Med. J., 1982, 284, 249–252

    Article  CAS  Google Scholar 

  25. Strandberg, K. Experience from the WHO collaborating centre for international drug monitoring. Drug Inf. J., 1985, 19, 385–390

    Google Scholar 

  26. McEwen, J. and Vhrovac, C.B., Panel on management of ADR reports in selected national centres. Drug. Inf. J., 1985, 19, 329–344

    Google Scholar 

  27. Griffin, J.P. and Weber, J.C.P., Voluntary systems of adverse reaction reporting Part II. Adv. Drug React. Ac. Pois. Rev., 1986, 1, 23–55

    Google Scholar 

  28. Griffin, J.P., Survey of the spontaneous ADR reporting schemes in 15 countries. Br. J. Clin. Pharmac., 1986, 22, 83S–100S

    Article  Google Scholar 

  29. Dukes, M.N.G. and Lunde, I., Common sense and communities. Pharm. Week bld., 1979, 144, 1283–1284

    Article  Google Scholar 

  30. Moore, N., Paux, G., Bégaud, B., Biour, M., Loupi, E., Boismare, F. and Royer, R.J. Adverse drug reaction monitoring — doing it the French way. Lancet, 1985, No. 9, 1056–1058

    Google Scholar 

  31. Laporte, J-R., Developing national systems. Spain as a model. Drug Inf. J., 1985, 19, 351–355

    Google Scholar 

  32. Laporte, J-R. Spain. In Monitoring for Drug Safety, 2nd edition, 1986, pp. 143–153

    Google Scholar 

  33. Poggiolini, D. Pharmaceutical Regulating Activities in Italy, EIS, Gladbach, W. Germany

    Google Scholar 

  34. Scrip., July 1983

    Google Scholar 

  35. Moussa, M.A.A., Bayoumi, A., Al-Khars, A.A. and Thulesius, O. Adverse drug reaction monitoring in Kuwait (1981–84). J. Clin. Pharmacol., 1985, 25, 176–181

    Article  PubMed  CAS  Google Scholar 

  36. Gartmann, J., Die Tätigkeit der Schweizerischen Arzneimittel-Nebenwirkungs-Zentrale (SANZ). Ther. Umschau, 1982, 39(11), 928–933

    CAS  Google Scholar 

  37. Ott, H., Qu’est-ce que le CSPV et comment fonctionne-t-il: notions juridiques. Bull. des médicines Suisses, 1981, 62, 18, 1326

    Google Scholar 

  38. Scrip, no. 516, 20 Aug, 1980, 8

    Google Scholar 

  39. Griffin, J.P. and Weber, J.C.P., Voluntary systems of adverse reaction reporting Part I. Adv. Drug React. Ac. Pois. Rev., 1985, 4, 213–230

    CAS  Google Scholar 

  40. Crombie, I., Inherent limitations of the yellow card system for the detection of unsuspected ADR. Human Toxicology, 1984, 3, 261–269

    Article  PubMed  CAS  Google Scholar 

  41. Beeley, L., Elliott, D. and Griffiths, K. Patterns in spontaneous reports sent to a regional ADR reporting centre. Acta Pharm. Toxicol, 1986, suppl. V. Abstract, 423, p. 159

    Google Scholar 

  42. Milstien, J.B., Faich, G.A., Hsu, J.P., Knapp, D.E., Baum, C. and Dreis, M.W. Factors affecting physician reporting of ADR. Drug. Inf. J., 1986, 20, 157–164

    Google Scholar 

  43. Faich, G.A., Special report ADR monitoring. N. Engl. J. Med., 1986, 314(24), 1589–1592

    Article  PubMed  CAS  Google Scholar 

  44. Anello, C., Scrip. No. 1146, Oct. 15, 1986, p. 16

    Google Scholar 

  45. Scrip. no. 1141, 29 Sep, 1986, 16

    Google Scholar 

  46. Follath, F., Burkart, F. and Schweizer, W. Drug-induced pulmonary hypertension. Br. Med. J., 1971, 1, 265

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  47. Fraumeni, J.F., Bone marrow depression induced by chloramphenicol and phenylbutazone, J.A.M.A., 1967, 20(1), 828

    Article  Google Scholar 

  48. Constant, K.W., Worlledge, S., Dollery, C.T. and Breckenridge, A. Methyl Dopa and haemolytic anaemia, Lancet, 1966, 1, 22 Jan, 201.

    Google Scholar 

  49. Rich, M.L., Rittehof, R.J. and Hoffmann, R.J. A fatal case of aplastic anaemia following chloramphenicol (Chloromycetin) therapy. Ann. Intern. Med., 1950, 33, 1459–1467

    Article  PubMed  CAS  Google Scholar 

  50. Wright, P.E. Skin reaction to practolol, Br. Med. J., 1974, 2, 560

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  51. Laganière, S. and Biron, P. Clinical Trials: Incomplete reporting of side effects, Curr. Ther. Res., 1979, 25(6), 743–746

    Google Scholar 

  52. Albin, H., Bégaud, B., Boisseau, A. and Dangoumau, J. Validation des publications d’effets indésirables par une méthode d’imputatilité. Thérapie, 1980, 35(5), 571–576

    PubMed  CAS  Google Scholar 

  53. Péré, J.-C., Bégaud, B., Albin, W. and Dangoumau, J., Effets indésirables non-descrits de l’observation aux données de la literature. Thérapie, 1981, 31, 237–240

    Google Scholar 

  54. Bégaud, B., Péré, J.-C. and Dangoumau, J. Mise en oeuvre d’un critère, la bibliographie. Thérapie, 1981, 36, 233–236

    PubMed  Google Scholar 

  55. Venulet, J., Blattner, R., Von Bülow, J. and Bernecker, G.C. How good are articles on ADR? Br. Med. J., 1982, 284, 252–254

    Article  CAS  Google Scholar 

  56. O’Connor, P.C., McCabe, J. and Lawson, D.H., Report of ADR in general medical journals, Irish J. Med. Sci., 1982, 151, 184–187

    Article  PubMed  Google Scholar 

  57. Joyce, C.R.B. and Joyce, J. Pyramidal publication. Eur. J. Clin. Pharmacol., 1983, 25, 1–2

    Article  Google Scholar 

  58. Davies, D.M. Special report. Adv. Drug. React. Ac. Pois. Rev., 1984, 3(4), 249–250

    Google Scholar 

  59. Venulet, J., Informativity of ADR data in medical publications. Drug Inf. J., 1985, 19, 357–365

    Google Scholar 

  60. Haramburu, F., Bégaud, B., Péré, J.C., Marcel, S. and Albin, H. Role of medical journals in ADR alerts, Lancet, 7 Sep, 1985, 2, 550–551

    Article  PubMed  CAS  Google Scholar 

  61. Rossi, A.C. and Knapp, D.E. Discovery of new ADR. A review of the FDA spontaneous reporting system, J.A.M.A., Aug 24/31, 1984, 252(8), 1030–1033

    Article  PubMed  CAS  Google Scholar 

  62. Dollery, C.T. and Rawlins, M.D., Monitoring adverse reactions to drugs. Br. Med. J., 1977, 1, 96–97

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  63. Lawson, D.H. and Henry, D.A. Monitoring adverse reactions to new drugs: restricted release or monitored release. Br. Med. J., 1977, 1, 691–692

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  64. Inman, W.H.W. Recorded release: a proposal for postmarketing surveillance of new drugs. Paper read at Symposium on Drug Control in General Practice, June 1977

    Google Scholar 

  65. Wilson, A.B. Postmarketing surveillance of adverse reactions to new medicines, Br. Med. J., 1977, 2, 1001–1003

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  66. Waiden, R.J. and Prichard, B.N.C. Postmarketing drug surveillance, Br. J. Clin Pharmacol., 1978, 6, 191–192

    Article  Google Scholar 

  67. C.S.M., Suggestions for monitoring adverse drug reactions. Pharm. J., 1977, 219, 9 July, 30–31

    Google Scholar 

  68. Smithells, R.N., The Liverpool Congenital Abnormality Registry. Develop. Med. Child Neurolog., 1962, 4, 320

    Article  CAS  Google Scholar 

  69. Smithells, R.N., Drug teratogenicity. In Monitoring for Drug Safety, 2nd edition (ed. W.H. Inman), MTP Press, pp. 383–390, 1986

    Google Scholar 

  70. Keeling, D.H. Radio pharmaceuticals. In Monitoring for Drug Safety, 2nd edition (ed. W.H. Inman), MTP Press, 1986, pp. 347–356

    Google Scholar 

  71. Banes, S.B. and Turner, P. Ophthalmic opticians and ocular ADR. Pharmaceutical Med., 1985, 1, 97–98

    Google Scholar 

  72. Scrip, no. 1122, 23 July 1986, 25

    Google Scholar 

  73. Fries, J.F. The ARAMIS (American rheumatism association medical information system) PMS program, Drug Inf. J., 1985, 19, 257–262

    Google Scholar 

  74. Fraunfelder, F.T., National registry of drug-induced ocular side effects. In Monitoring for Drug Safety (ed. W.H.N. Inman), 2nd edition, 1986

    Google Scholar 

  75. Postmarketing surveillance of prescription drugs, Office of Technology assessment, No. 1982, p. 42. Library of Congress Catalog Card No. 82–600 652

    Google Scholar 

  76. Jones, J.K., Faich, G.A. and Anello, C. The United States of America. In Monitoring for Drug Safety, 2nd edition (ed. W.H. Inman), MTP Press, p. 157

    Google Scholar 

  77. Edlavitch, S.A., Feinleib, M. and Anello C. A potential use of the national death index for postmarketing surveillance, J.A.M.A., 1985, 253, 1292–1295

    Article  PubMed  CAS  Google Scholar 

  78. Wiholm, B.E. Spontaneous reporting of ADR. Cross-fertilisation with register data on morbidity and drug utilisation. In Detection and Prevention of ADR (ed. H. Boström and N.L. Jungstedt), Almqvist and Wiksell, Stockholm, pp. 152–167

    Google Scholar 

  79. Idänpään Heikkilä, J. Finland. In Monitoring for Drug Safety, 2nd edition (ed. W.H. Inman), MTP Press, 1986, pp. 83–92

    Google Scholar 

  80. Grohmann, R., Hippius, H., Müller-Oerlinghausen, B., Ruther, E. Scherer, J., Schmidt, L.G., Strauss, A. and Wolf, B., Assessment of adverse drug reactions in psychiatric hospitals, Eur. J. Clin. Pharmacol., 1984, 26, 727–734

    Article  PubMed  CAS  Google Scholar 

  81. Bruinsma W. A Guide to Drug Eruptions, 4th edition, De Zwaluw, P.O. Box 21, Oosthuizen, The Netherlands, 1986

    Google Scholar 

  82. Lawson, D.H., Intensive monitoring studies in hospitals. In Monitoring for Drug Safety, 2nd edition (ed. W.H. Inman), M.T.P. Press, 1986, pp. 255–276

    Google Scholar 

  83. Jick, H., Boston collaborative drug surveillance program. In Monitoring for ADR, (ed. S.R. Walker and A. Goldberg), MTP Press, 1984

    Google Scholar 

  84. Miller, R.R., Comprehensive prospective drug surveillance, a report from the BCDSP. Pharmaceutisch Weekblad., 1973, 109(20), 461–481

    Google Scholar 

  85. Cohen, M.R. A compilation of abstracts and an index of articles published by the BCDSP. Hospital Pharm., 1974, 9, 437–448

    Google Scholar 

  86. Porter, J.B., Beard, M., Walker, A.M., Lawson, D.H., Jick, H. and Kellaway, G.S.M. Intensive hospital monitoring study of intravenous Cimetidine. Arch. Intern. Med., 1986, 146, 2237–2239

    Article  PubMed  CAS  Google Scholar 

  87. Moir, D.C. Intensive monitoring in hospitals, The Aberdeen-Dundee System. In Monitoring for Drug Safety, 2nd edition (ed. W.H. Inman), MTP Press, 1986, pp. 277–291

    Google Scholar 

  88. Friedman, G.D., Screening criteria for drug monitoring. The Kaiser-Permanente drug reaction monitoring sytem. J. Chron. Dis., 1972, 25, 11–20

    Article  PubMed  CAS  Google Scholar 

  89. Friedman, G.D., Collen, M.F., Harris, L.E., Van Brunt, E.E. and Davis, L.S. Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente drug monitoring system. J.A.M.A., 1971, 217(5), 567–572

    Article  PubMed  CAS  Google Scholar 

  90. Jones, J.K. Postmarketing surveillance. An FDA perspective presented at the annual Society for Clinical Pharmacology and Therapeutics Postgraduate course, New Orleans, 1981

    Google Scholar 

  91. Jick, H., Madsen, S., Nudelman, P.M., Perera, D.R. and Stergachis, A. Postmarketing follow-up of Group Health co-operative of Puget Sound. Pharmacotherapy, 1984, 4(2), 99–100

    Article  PubMed  CAS  Google Scholar 

  92. Morse, M.L., Le Roy, A.A. and Strom, B.L. The Computerised On-line Medicaid Pharmaceutical Analysis and Surveillance System (COMPASS). In Monitoring for Drug Safety (ed. W.H. Inman), 2nd edition, MTP Press, 1986

    Google Scholar 

  93. Morse, M.L., The COMPASS data base, Drug Inf. J., 1985, 19(3), 249–253

    Google Scholar 

  94. Carson, J.L. COMPASS data base. An epidemiologist’s viewpoint. Proceedings of the 20th annual meeting of Drug Information Association, pp. 97–100, 1984

    Google Scholar 

  95. Carson, J.L. and Strom, B.L., Technique of postmarketing surveillance. An overview. Medical Toxicology, 1986, 1, 237–246

    PubMed  CAS  Google Scholar 

  96. Strom, B.L., Carson, J.L., Morse, M.L. and Leroy, A.A., The computerised on-line Medicaid pharmaceutical analysis and surveillance system. A new resource for postmarketing drug surveillance. Clin. Pharmacol. Ther., 1985, 38(4), 350–364

    Article  Google Scholar 

  97. Faich, G.A., Postmarketing surveillance of prescription drugs. Current status, 1986, Clinical Real Life Studies Program, Clinical Medicine Research Institute, 800 Second Ave, New York

    Google Scholar 

  98. Federspiel, C.F., Wayne, R.A. and Schaffner, W. Medicaid records as a valid data source: The Tennessee experience. Medical Care, 1976, 14, 166–172

    Article  PubMed  CAS  Google Scholar 

  99. Finkle, W.D. Studies of drug effects within the Kaiser Foundation Health Plan, Southern California region. Drug Inf. J., 1985, 19, 243–247

    Google Scholar 

  100. Stewart, R.B., Hale, W.E. and Marks, R.G. Drug use and ADR in an ambulatory elderly population: a review of the Dunedin program, Pharm. Int., 1984, pp. 149–152

    Google Scholar 

  101. Strand, L.M., Drug epidemiology resources and studies: The Saskatchewan data base, Drug Inf. J., 1985, 19, 253–256

    Google Scholar 

  102. Guess, H.A., West, R., Strand, L.M., Heiston, D., Lydick, E.G., Bergman, U. and Wolski, K.P. Fatal gastro-intestinal bleeding amongst users and non-users of non-steroidal anti-inflammatory drugs (NSAID) in Saskatchewan, Canada 1983. J. Clin. Epidemiol., 1988, 41, 35–45

    Article  PubMed  CAS  Google Scholar 

  103. Crombie, I.K., Dundee record linkage study. In Monitoring for ADR (ed. S. Walker and A. Goldberg), MTP Press, 1984

    Google Scholar 

  104. Crombie, I.K., Brown, S.V. and Hamley, J.G., Postmarketing drug surveillance by record linkage in Tayside, J. Epidemiology and Community Health, 1984, 38, 226–231

    Article  CAS  Google Scholar 

  105. Beardon, P.H.G., Brown, S.V. and McDevitt, D.G., Postmarketing surveillance by record linkage in Tayside. Follow-up morbidity study of Cimetidine. Acta Pharm. Toxicol., 1986, suppl. V. Abstract 414, p. 157

    Google Scholar 

  106. Crombie, I.K. The role of record linkage in postmarketing surveillance. Br. J. Clin. Pharmacol., 1986, 22, 775–825

    Article  Google Scholar 

  107. Lawson, D.H., Postmarketing surveillance in the UK 1984, Br. J. Clin. Pharmacol., 1986, 22, 71S–75S

    Article  PubMed  PubMed Central  Google Scholar 

  108. McDevitt, D.G., Bearden, P.H.G. and Brown, S.V. Mortality amongst Cimetidine takers: results of a long-term follow-up study using record linkage. Acta Pharm. Toxicol., 1986, suppl. Abstract 415, 157

    Google Scholar 

  109. Skegg, D.C.G., Medical record linkage. In Monitoring for Drug Safety, 1st edition (ed. W.H.W. Inman), MTP Press

    Google Scholar 

  110. Sjöquist, F. and Boethius, G. Attitude to development of drug therapy in Scandinavia. Br. J. Clin. Pharmacol., 1986, 22, 19S–26S

    Article  Google Scholar 

  111. Inman, W.H.W., Rawson, N.S.B. and Wilton, L.V. Prescription Event Monitoring. In Monitoring for Drug Safety, 2nd edition (ed. W.H. Inman), MTP Press, 1986

    Google Scholar 

  112. Inman, W.H.W., Postmarketing surveillance of adverse drug reaction in general practice (i) Search for new methods, Br. Med. J., 1981, 282, 1131–1132

    Article  CAS  Google Scholar 

  113. Inman, W.H.W. Postmarketing surveillance of adverse drug reaction in general practice (ii) PEM at the University of Southampton, Br. Med. J., 1981, 282, 1216–1217

    Article  CAS  Google Scholar 

  114. Drug Surveillance Research Unit: PEM News, vol. 1 1983; PEM News, vol. 2 1984; PEM News, vol. 3 1985; PEM News, vol. 4 1987; Hamble Valley Press, Southampton

    Google Scholar 

  115. Rawlins, M.D., Postmarketing surveillance of adverse reactions to drugs, Br. Med. J., 1984, 288, 879–880

    Article  CAS  Google Scholar 

  116. Lawson, D.H., Postmarketing surveillance in UK: a study of Cimetidine recipients. In Drug Safety and Controversies (ed. M. Auriche, J. Burke and J. Duchier), Pergamon Press, 1981

    Google Scholar 

  117. Colin-Jones, D.G., Langman, M.J.S., Lawson, D.H. and Vessey, M.P. Postmarketing surveillance. In Cimetidine in the 80s (ed. J.H. Baron), Churchill, Livingstone, 1981

    Google Scholar 

  118. Colin-Jones, D.G., Langman, M.J.S., Lawson, D.H. and Vessey, M.P. Postmarketing surveillance of the safety of Cimetidine, 12 monthly mortality report, Br. Med. J., 1983, 286, 1713–1716

    Article  CAS  Google Scholar 

  119. An experiment in early PMS of new drugs, prepared for the FDA, 24 Oct 1978, IMS America Ltd, Ambler, PA., pp. 214–231

    Google Scholar 

  120. Oral Contraceptives and Health, The Royal College of General Practitioners, 1974, Pitman

    Google Scholar 

  121. Scrip, no. 1158, 26 Nov 1986, 26

    Google Scholar 

  122. The Guardian, 28 Nov 1984

    Google Scholar 

  123. Horwitz, R.I. and Feinstein, A.R. The application of therapeutic trial principles to improve the design of epidemiological research — a case control study suggesting that anticoagulants reduce mortality in patients with myocardial infarction. J. Chron. Dis., 1981, 34, 575–581

    Article  PubMed  CAS  Google Scholar 

  124. Mantel, N. and Haenszell, W. Statistical aspects of the analysis of data from retrospective studies of disease, J. Natl. Cancer Inst., 1959, 22, (4), 719–748

    PubMed  CAS  Google Scholar 

  125. Sackett, D.L. Bias in analytical research. J. Chron. Dis., 1979, 32, 51–63

    Article  PubMed  CAS  Google Scholar 

  126. Smith, M.W. The case control or retrospective study: in retrospect. J. Clin. Pharmacol., 1981, 21, 269–274

    Article  PubMed  CAS  Google Scholar 

  127. Horwitz, R.I. and Feinstein, A.R. The problem of protopathic bias in case control studies. Am. J. Med., 1980, 68, 255–258

    Article  PubMed  CAS  Google Scholar 

  128. Vessey, M.P. Case-control studies in the assessment of drug safety. Acta Med. Scand., 1984, suppl. 683, 29–33

    Google Scholar 

  129. Spriet-Pourra, C., Postmarketing surveillance by the drug industry. Discussion on postmarketing surveillance of drug effects organised by the Drug Surveillance Research Unit on behalf of the European Community, Southampton, 8–10 April, 1981

    Google Scholar 

  130. Pryor, J.P. and Castle, W.M. Peyronie’s disease associated with chronic degenerative arterial disease and not with beta-adrenoceptor blocking agents. Lancet, 1982, 1, 17 April, 917

    Article  PubMed  CAS  Google Scholar 

  131. The International Study of Agranulocytosis and Aplastic Anaemia 1983. The design of a study of the drug aetiology of agranulocytosis and aplastic anaemia. Eur. J. Clin. Pharmacol., 1983, 12, 653–658

    Google Scholar 

  132. The International Agranulocytosis and Aplastic Anaemia study. Risks of agranulocytosis and aplastic anaemia. A first report of their relation to drug use with special reference to analgesics, J.A.M.A. 3rd Oct 1986, 256, 13, 1749–1757

    Google Scholar 

  133. Scrip, no. 1128, 13 Aug 1986, p. 22

    Google Scholar 

  134. Rosenberg, L. Postmarketing surveillance. The approach of the drug epidemiology unit. Drug Inf. J., 1985, 19, 263–268

    Google Scholar 

  135. Westlin, W.F., Cuddihy, R.V., Bursik, R.J., Seifert, B.G. and Koelle, J.G. One method for the systematic evaluation of adverse drug experience data within a pharmaceutical firm, Methods Inf. Med., 1977, 16(4), 240–247

    PubMed  CAS  Google Scholar 

  136. Castle, W.M. Placing adverse reaction reports in perspective. In Proceedings 7th Annual conference of AIOPI, 1980, pp. 48–50

    Google Scholar 

  137. Bégaud, B., Péré, J-C. and Dangoumau, J., Mise en oeuvre d’une critère la bibliographie, Thérapie, 1981, 36, 233–236

    PubMed  Google Scholar 

  138. Sills, J.M., Faich, G.A., Milstien, J.B. and Turner, W.M. Postmarketing reporting of ADR to the FDA. An overview of the 1985 FDA guideline, Drug Inf. J., 1986, 20, 151–156

    Google Scholar 

  139. Trombitas, I.D. and Simpson, R.L. Monitoring the world’s published literature for adverse drug experience. Drug Inf. J., 1986, 20, 57–62

    Google Scholar 

  140. Venulet, J., Informativity of ADR data in medical publications. Drug Inf. J., 1985, 19, 357–365

    Google Scholar 

  141. Scrip. No. 1012, 1st July 1985, p. 6

    Google Scholar 

  142. Sullman, S.F. A resumé of the pharmaceutical industry’s experience with monitored release. In Postmarketing surveillance of adverse reactions to new medicines. Medico-Pharmaceutical Forum, Publication No. 7, 1977

    Google Scholar 

  143. Stephens, M.D.B. The detection of new adverse drug reactions, 1st edition, Macmillan Press, p. 116

    Google Scholar 

  144. Fauchald, P., Helgeland, A. and Storm-Mathison. Treatment of hypertension with prazosin. An open study in general practice. Proceedings of the European Prazosin Symposium, 1978, Excerpta Medica

    Google Scholar 

  145. Rossi, A-C., Knapp, D.E., Anello, C., O’Neill, R.T., Graham, C.F., Mendelis, P.S. and Stanley, G.R. Discovery of adverse drug reactions. A comparison of selected Phase IV studies with spontaneous reporting methods, J.A.M.A., 1983, 249, 2226–2228

    Article  PubMed  CAS  Google Scholar 

  146. Anello, C. The use, design and limitations of selected Phase IV studies in the USA. Droit et Pharmacie Essais Cliniques Postmarketing, 1983, Editions de Santé

    Google Scholar 

  147. Perry-Evans, D. Monitoring adverse reactions to drugs, M.D. Thesis, University of London 1976

    Google Scholar 

  148. Stephens, M.D.B. Comprehensive drug surveillance. Pharmaceutical company viewpoint. In Monitoring for Adverse Drug Reactions (ed. S.R. Walker and A. Goldberg) MTP Press, 1983

    Google Scholar 

  149. Borden, E.K. Postmarketing drug surveillance, J.A.M.A., 1984, 251(6), 729–730

    Article  PubMed  CAS  Google Scholar 

  150. Rogers, A. and Tilson, H. Postmarketing surveillance. The Sponsor’s viewpoint. Proceedings of the DIA Meeting, June 1984, San Diego, pp. 101–105

    Google Scholar 

  151. Tilson, H., Methodologic issues in postmarketing surveillance. Pharmaceutical industry’s view — Burroughs Wellcome. Drug Inf. J., 1985, 19, 275–283

    Google Scholar 

  152. Scrip. No. 951, 21 Nov 1984, p. 15

    Google Scholar 

  153. Borden, E.K. and Lee, J.G. A methodologic study of postmarketing drug evaluation using a pharmacy based approach. J. Chron. Dis, 1982, 35, 803–816

    Article  PubMed  CAS  Google Scholar 

  154. Luscombe, F.A., Methodologic issues in Pharmacy based PMS. Drug Inf. J., 1985, 19, 269–274

    Google Scholar 

  155. Borden, E.K., Gardner, J.S., Westland, M. and Gardner, S.D., Postmarketing surveillance, J.A.MA., 10 Feb 1984, 251(6), 729

    CAS  Google Scholar 

  156. Linden, C.V. and Barry, W.S., Drug experience reporting in a US based multinational corporation. Acta Pharm. Toxicol., 1986, suppl. V: III World Conference on Clinical Pharmacology and Therapeutics 1986, Abstract 425, 159

    Google Scholar 

  157. Wallander, A.M-A. and Palmer, L.S. A monitoring system for adverse drug experience in a Pharmaceutical company — the integration of pre and postmarketing data. Drug Inf. J., 1986, 20, 225–235

    Google Scholar 

  158. Colin-Jones, D.G., Langman, M.J.S., Lawson, D.H. and Vessey, M.P. PMS of the safety of Cimetidine: twelve-month morbidity report. Quarterly J. Med., 1985, New Series 54, 215, 253–268

    Google Scholar 

  159. Colin-Jones, D.G., Langman, M.J.S., Lawson, D.H. and Vessey, M.P. PMS of the safety of Cimetidine morbidity during 2, 3 and 4th years of follow-up. Br. Med. J., 1985, 291, 1084–1088

    Article  CAS  Google Scholar 

  160. Colin-Jones, D.G., Langman, M.J.S., Lawson, D.H. and Vessey, M.P. Cimetidine and gastric cancer: preliminary report from PMS study. Br. Med. J., 1982, 285, 1311–1313

    Article  CAS  Google Scholar 

  161. Davis, T.G., Pickett, D.L. and Schlosser, J.M. Evaluation of a worldwide spontaneous reporting system with Cimetidine. J.A.M.A., 1980, 243(19), 1912–1914

    Article  PubMed  CAS  Google Scholar 

  162. Gifford, L.M., Aeugle, M.E., Myerson, R.M., Tannenbaum, P.J. Cimetidine postmarket outpatient surveillance program. J.A.M.A., 1980, 243(15), 1532–1535

    Article  PubMed  CAS  Google Scholar 

  163. McDevitt, D.G., Beardon, P.H.G. and Brown, S.V. Mortality amongst Cimetidine takers: results of a long term follow-up study using record linkage. Acta Pharm. Toxicol., 1986, suppl. V. Abstracts 414 and 415

    Google Scholar 

  164. Sneader, W. In Drug Development from Laboratory to Clinic, Wiley, 1986

    Google Scholar 

  165. Lawson, D.H., Chalmers, D. and Dombey, S. PMS of Captopril for hypertension, Abstract 730, Acta Pharm. Toxicol., 1986, suppl. V. Abstract 730, p. 156

    Google Scholar 

  166. Chalmers, D. A PMS study of Captopril utilising viewdata technology, Abstract. International symposium evaluation of the risk benefit profile in the PMS of the drug, Bergamo, Italy, Oct. 1985

    Google Scholar 

  167. Maclay, W.P., Crowder, D., Spiro, S. and Turner, P. PMS practical experience with Ketotifen. Br. Med. J., 1984, 288, 911–914

    Article  CAS  Google Scholar 

  168. Maclay, W.P., Chapter 2.4: Cohort or case approach to validation of ADRs. In Monitoring for ADR (ed. S.R. Walker and A. Goldberg), MTP Press Ltd, 1984, pp. 69–72

    Google Scholar 

  169. Goldsmith, D.I., Yen, C.C. and Greenberg, B.P. A comprehensive system for international pharmaceutical company monitoring of ADR. Drug Inf. J., 1986, 20, 305–310

    Google Scholar 

Download references

Authors
  1. M. D. B. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

Copyright information

© 1988 M.D.B. Stephens

About this chapter

Cite this chapter

Stephens, M.D.B. (1988). Post-marketing Surveillance (PMS). In: The Detection of New Adverse Drug Reactions. Palgrave, London. https://doi.org/10.1007/978-1-349-09887-3_6

Download citation

Publish with us

Policies and ethics

Search

Navigation